Patanjali Ravva

559 total citations
17 papers, 420 citations indexed

About

Patanjali Ravva is a scholar working on Molecular Biology, Epidemiology and Physiology. According to data from OpenAlex, Patanjali Ravva has authored 17 papers receiving a total of 420 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Epidemiology and 4 papers in Physiology. Recurrent topics in Patanjali Ravva's work include Smoking Behavior and Cessation (4 papers), Influenza Virus Research Studies (3 papers) and Statistical Methods in Clinical Trials (3 papers). Patanjali Ravva is often cited by papers focused on Smoking Behavior and Cessation (4 papers), Influenza Virus Research Studies (3 papers) and Statistical Methods in Clinical Trials (3 papers). Patanjali Ravva collaborates with scholars based in United States, United Kingdom and Switzerland. Patanjali Ravva's co-authors include Hélène M. Faessel, Mats O. Karlsson, Kathryn Williams, Ping Liu, Lena E. Friberg, Marc R. Gastonguay, R. Scott Obach, Thomas G. Tensfeldt, Aaron H. Burstein and Hans Rollema and has published in prestigious journals such as Blood, Antimicrobial Agents and Chemotherapy and Annals of the Rheumatic Diseases.

In The Last Decade

Patanjali Ravva

17 papers receiving 410 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patanjali Ravva United States 10 115 111 110 107 72 17 420
Marissa F. Dockendorf United States 15 117 1.0× 40 0.4× 158 1.4× 78 0.7× 87 1.2× 31 545
Shengyuan Liu China 14 40 0.3× 136 1.2× 141 1.3× 138 1.3× 47 0.7× 34 539
Belle L. Lee United States 12 83 0.7× 112 1.0× 438 4.0× 215 2.0× 125 1.7× 15 835
John F. French United States 15 128 1.1× 174 1.6× 114 1.0× 179 1.7× 31 0.4× 26 659
Anna Gottschlich Canada 11 92 0.8× 111 1.0× 61 0.6× 209 2.0× 40 0.6× 37 722
John Alimamy Kabba China 12 83 0.7× 88 0.8× 24 0.2× 71 0.7× 37 0.5× 26 502
Krista Goodman United States 12 62 0.5× 90 0.8× 91 0.8× 75 0.7× 21 0.3× 17 436
Nataša Djordjević Serbia 15 31 0.3× 174 1.6× 56 0.5× 61 0.6× 123 1.7× 48 716
Jean‐Pierre Jourdan France 9 56 0.5× 157 1.4× 45 0.4× 43 0.4× 48 0.7× 18 507
Annika C. Montag United States 10 25 0.2× 100 0.9× 42 0.4× 80 0.7× 18 0.3× 20 442

Countries citing papers authored by Patanjali Ravva

Since Specialization
Citations

This map shows the geographic impact of Patanjali Ravva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patanjali Ravva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patanjali Ravva more than expected).

Fields of papers citing papers by Patanjali Ravva

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patanjali Ravva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patanjali Ravva. The network helps show where Patanjali Ravva may publish in the future.

Co-authorship network of co-authors of Patanjali Ravva

This figure shows the co-authorship network connecting the top 25 collaborators of Patanjali Ravva. A scholar is included among the top collaborators of Patanjali Ravva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patanjali Ravva. Patanjali Ravva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Nayak, Satyaprakash, Michael P. Wajnrajch, Joan Korth‐Bradley, et al.. (2025). IGF-1 Assessment During Weekly Somatrogon Treatment in Pediatric Patients With GH Deficiency. Journal of the Endocrine Society. 9(2). bvaf001–bvaf001. 2 indexed citations
2.
Ravva, Patanjali, et al.. (2025). Population Modeling of Factor IX Activity Following Administration of Fidanacogene Elaparvovec Gene Therapy in Participants with Hemophilia B. Clinical Pharmacokinetics. 64(10). 1531–1548. 1 indexed citations
3.
4.
Gibiansky, Leonid, Annabelle Lemenuel‐Diot, Patanjali Ravva, et al.. (2021). Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy. British Journal of Clinical Pharmacology. 88(3). 1189–1201. 1 indexed citations
5.
Lemenuel‐Diot, Annabelle, Kashyap Patel, Leonid Gibiansky, et al.. (2020). Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug‐disease modelling for dosing regimen optimization. British Journal of Clinical Pharmacology. 87(3). 1359–1368. 3 indexed citations
6.
Gibiansky, Leonid, et al.. (2020). Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and Infants. Clinical Pharmacology & Therapeutics. 108(1). 126–135. 4 indexed citations
7.
Sostelly, Alexandre, Guillemette Duchâteau-Nguyen, Claire Petry, et al.. (2019). OP0224 RESULTS OF A PHASE 2 STUDY OF RG6125, AN ANTI-CADHERIN-11 MONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO ANTI-TNFALPHA THERAPY. Annals of the Rheumatic Diseases. 78. 189–189. 17 indexed citations
8.
9.
Bonate, Peter L., Malidi Ahamadi, Nageshwar Budha, et al.. (2016). Methods and strategies for assessing uncontrolled drug–drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group. Journal of Pharmacokinetics and Pharmacodynamics. 43(2). 123–135. 21 indexed citations
10.
Ravva, Patanjali, Marc R. Gastonguay, Hélène M. Faessel, Theodore C. Lee, & Raymond Niaura. (2014). Pharmacokinetic-Pharmacodynamic Modeling of the Effect of Varenicline on Nicotine Craving in Adult Smokers. Nicotine & Tobacco Research. 17(1). 106–113. 11 indexed citations
11.
Ravva, Patanjali, Mats O. Karlsson, & Jonathan French. (2014). A linearization approach for the model‐based analysis of combined aggregate and individual patient data. Statistics in Medicine. 33(9). 1460–1476. 9 indexed citations
12.
Friberg, Lena E., Patanjali Ravva, Mats O. Karlsson, & Ping Liu. (2012). Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults. Antimicrobial Agents and Chemotherapy. 56(6). 3032–3042. 119 indexed citations
13.
Ravva, Patanjali, Marc R. Gastonguay, Jonathan French, Thomas G. Tensfeldt, & Hélène M. Faessel. (2010). Quantitative Assessment of Exposure–Response Relationships for the Efficacy and Tolerability of Varenicline for Smoking Cessation. Clinical Pharmacology & Therapeutics. 87(3). 336–344. 18 indexed citations
14.
Gastonguay, Marc R., Jonathan French, Daniel F. Heitjan, et al.. (2010). Missing Data in Model‐Based Pharmacometric Applications: Points to Consider. The Journal of Clinical Pharmacology. 50(S9). 63S–74S. 22 indexed citations
15.
Faessel, Hélène M., R. Scott Obach, Hans Rollema, et al.. (2010). A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation. Clinical Pharmacokinetics. 49(12). 799–816. 89 indexed citations
16.
Faessel, Hélène M., Patanjali Ravva, & Kathryn Williams. (2009). Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics. 31(1). 177–189. 50 indexed citations
17.
Ravva, Patanjali, Marc R. Gastonguay, Thomas G. Tensfeldt, & Hélène M. Faessel. (2009). Population pharmacokinetic analysis of varenicline in adult smokers. British Journal of Clinical Pharmacology. 68(5). 669–681. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marissa F. Dockendorf Breakdown of academic impact, for papers by Shengyuan Liu Breakdown of academic impact, for papers by Belle L. Lee Breakdown of academic impact, for papers by John F. French Breakdown of academic impact, for papers by Anna Gottschlich Breakdown of academic impact, for papers by John Alimamy Kabba Breakdown of academic impact, for papers by Krista Goodman Breakdown of academic impact, for papers by Nataša Djordjević Breakdown of academic impact, for papers by Jean‐Pierre Jourdan Breakdown of academic impact, for papers by Annika C. Montag
Rankless by CCL
2026